Shopping Cart
- Remove All
Your shopping cart is currently empty
(S,R,S)-AHPC-PEG2-N3
Catalog No. T17913Cas No. 2010159-45-0
Alias VHL Ligand-Linker Conjugates 6, VH032-PEG2-N3, E3 ligase Ligand-Linker Conjugates 13
(S,R,S)-AHPC-PEG2-N3 (VHL Ligand-Linker Conjugates 6) is a synthesized E3 ligase ligand-linker conjugate comprising a (S,R,S)-AHPC-based VHL ligand and a 2-unit PEG linker.
(S,R,S)-AHPC-PEG2-N3
Catalog No. T17913Alias VHL Ligand-Linker Conjugates 6, VH032-PEG2-N3, E3 ligase Ligand-Linker Conjugates 13Cas No. 2010159-45-0
(S,R,S)-AHPC-PEG2-N3 (VHL Ligand-Linker Conjugates 6) is a synthesized E3 ligase ligand-linker conjugate comprising a (S,R,S)-AHPC-based VHL ligand and a 2-unit PEG linker.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $33 | In Stock | |
| 5 mg | $74 | In Stock | |
| 10 mg | $106 | In Stock | |
| 25 mg | $158 | In Stock | |
| 50 mg | $216 | In Stock | |
| 100 mg | $363 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "(S,R,S)-AHPC-PEG2-N3"
Lenalidomide
Cited
CC-5013
T1642191732-72-6
Lenalidomide (CC-5013) is an immunomodulator with oral activity. Lenalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN), which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase, and is commonly used in the synthesis of PROTAC products.
- $36
Size
QTY
CitedLenalidomide Cited
CC-5013
T1642191732-72-6
Lenalidomide (CC-5013) is an immunomodulator with oral activity. Lenalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN), which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase, and is commonly used in the synthesis of PROTAC products.
- $36
Size
QTY
CitedLenalidomide Cited
CC-5013
T1642191732-72-6
Lenalidomide (CC-5013) is an immunomodulator with oral activity. Lenalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN), which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase, and is commonly used in the synthesis of PROTAC products.
- $36
Size
QTY
CitedLenalidomide Cited
CC-5013
T1642191732-72-6
Lenalidomide (CC-5013) is an immunomodulator with oral activity. Lenalidomide is a ligand for the ubiquitin E3 ligase cereblon (CRBN), which selectively ubiquitinates and degrades two lymphoid transcription factors, IKZF1 and IKZF3, via the CRBN-CRL4 ubiquitin ligase, and is commonly used in the synthesis of PROTAC products.
- $36
Size
QTY
CitedLenalidomide-Br
T180642093387-36-9
Lenalidomide-Br (Compound 41), a derivative of Lenalidomide, acts as a ligand for cereblon (CRBN) - an E3 ubiquitin ligase involved in protein recruitment. This compound can be conjugated to a protein ligand via a linker to create PROTACs, such as the PROTAC STAT3 degrader SD-36.
- $29
Size
QTY
Lenalidomide-Br
T180642093387-36-9
Lenalidomide-Br (Compound 41), a derivative of Lenalidomide, acts as a ligand for cereblon (CRBN) - an E3 ubiquitin ligase involved in protein recruitment. This compound can be conjugated to a protein ligand via a linker to create PROTACs, such as the PROTAC STAT3 degrader SD-36.
- $29
Size
QTY
Thalidomide Cited
Thalomid, Sedoval
T021350-35-1
Thalidomide (Thalomid) is a synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.
- $50
Size
QTY
CitedThalidomide Cited
Thalomid, Sedoval
T021350-35-1
Thalidomide (Thalomid) is a synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.
- $50
Size
QTY
CitedThalidomide Cited
Thalomid, Sedoval
T021350-35-1
Thalidomide (Thalomid) is a synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.
- $50
Size
QTY
CitedThalidomide Cited
Thalomid, Sedoval
T021350-35-1
Thalidomide (Thalomid) is a synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.
- $50
Size
QTY
CitedSelect Batch
Purity:99.33%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | (S,R,S)-AHPC-PEG2-N3 (VHL Ligand-Linker Conjugates 6) is a synthesized E3 ligase ligand-linker conjugate comprising a (S,R,S)-AHPC-based VHL ligand and a 2-unit PEG linker. |
| Alias | VHL Ligand-Linker Conjugates 6, VH032-PEG2-N3, E3 ligase Ligand-Linker Conjugates 13 |
| Molecular Weight | 601.72 |
| Formula | C28H39N7O6S |
| Cas No. | 2010159-45-0 |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 40 mg/mL (66.48 mM), Sonication is recommended. Ethanol: 80 mg/mL (132.95 mM) | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMSO/Ethanol
Ethanol
| |||||||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy (S,R,S)-AHPC-PEG2-N3 | purchase (S,R,S)-AHPC-PEG2-N3 | (S,R,S)-AHPC-PEG2-N3 cost | order (S,R,S)-AHPC-PEG2-N3 | (S,R,S)-AHPC-PEG2-N3 chemical structure | (S,R,S)-AHPC-PEG2-N3 formula | (S,R,S)-AHPC-PEG2-N3 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.